KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Takeda Pharmaceutical (TAK) Total Non-Current Liabilities (2018 - 2025)

Takeda Pharmaceutical (TAK) has 7 years of Total Non-Current Liabilities data on record, last reported at $31.5 billion in Q1 2025.

  • For Q1 2025, Total Non-Current Liabilities fell 15.46% year-over-year to $31.5 billion; the TTM value through Mar 2025 reached $31.5 billion, down 15.46%, while the annual FY2025 figure was $31.5 billion, 17.6% down from the prior year.
  • Total Non-Current Liabilities reached $31.5 billion in Q1 2025 per TAK's latest filing, down from $37.3 billion in the prior quarter.
  • Across five years, Total Non-Current Liabilities topped out at $56.3 billion in Q1 2021 and bottomed at $31.5 billion in Q1 2025.
  • Average Total Non-Current Liabilities over 5 years is $42.0 billion, with a median of $38.7 billion recorded in 2023.
  • Peak YoY movement for Total Non-Current Liabilities: increased 3.63% in 2021, then decreased 18.29% in 2022.
  • A 5-year view of Total Non-Current Liabilities shows it stood at $56.3 billion in 2021, then fell by 18.29% to $46.0 billion in 2022, then fell by 15.88% to $38.7 billion in 2023, then fell by 3.76% to $37.3 billion in 2024, then decreased by 15.46% to $31.5 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Total Non-Current Liabilities were $31.5 billion in Q1 2025, $37.3 billion in Q1 2024, and $38.7 billion in Q1 2023.